Cilengitide Imaging Trial in Glioblastoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main purpose of this clinical trial is to find out if cilengitide has an effect on brain tumor cells but also particularly on the blood vessels supplying the tumor with nutrient and oxygen in patients newly diagnosed with non-resectable (inoperable) glioblastoma.
In addition, this clinical trial will investigate if the addition of cilengitide in combination with standard treatment prolongs life in patients with non-resectable glioblastoma. Similarly, the duration of response of the cancer to this treatment and the side effects of the therapy will be analyzed. Furthermore, additional data on how the body deals with this substance will be collected (this is called pharmacokinetics or pharmacokinetic (PK) analysis). In this clinical trial the investigators would also like to learn more about the disease and the response to the experimental medication by measuring certain "markers".
This imaging trial will investigate the biological effects of cilengitide monotherapy on the tumor microvascular function and tumor viability in a homogenous non-pretreated subject population with newly diagnosed Gliobastoma (GBM). The purpose of this clinical trial is to study the effect that cilengitide may have on certain markers of cancer in your tumor and/or blood and to learn if there are any disease-related markers that could help in predicting how subjects respond to the administration of cilengitide.
The investigators anticipate that approximately 30 subjects will participate in this clinical trial. The clinical trial will be conducted in approximately 4 medical centers in the following countries: Germany, Poland, and Switzerland. The investigators anticipate the clinical trial will last until the end of 2013. Your participation in the trial may last up to 86 weeks.
| Condition | Intervention | Phase |
|---|---|---|
|
Supratentorial Newly Diagnosed Inoperable Gliobastoma |
Drug: Drug (including placebo) Other: Standard therapy |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | A Multi-center, Open-label, Randomized, Controlled Phase I Trial to Investigate the Effects of Cilengitide (EMD 121974) Using Dynamic MR and FET-PET Imaging as a Pharmacodynamic Measure of Response in Subjects With Newly Diagnosed Glioblastoma |
- Rate constant for passive contrast agent plasma/interstitium transfer (ktrans) [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]Any change in tumor kinetic model parameter (maximum increase in ktrans) to assess the tumor microvasculature structure and function
- Fractional blood plasma volume (vp) [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]Any change in tumor kinetic model parameter (maximum change in vp) to assess the tumor microvasculature structure and function
- Maximum tumor to brain ratio (TBRmax) [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]Assessment of tumor amino acid (FET) uptake (tumor viability)
- Total tumor volume and enhancing tumor volume [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]Change in total tumor volume and enhancing tumor volume as a measure of the overall level of tumor perfusion during the first 2 weeks of treatment with Cilengitide monotherapy
- Interstitial space volume fraction (putative contrast agent distribution volume) (=ve) [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]Change in the tumor extravascular extracellular space volume during the first 2 weeks of treatment with Cilengitide monotherapy
- Apparent Diffusion coefficient (ADC) [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]Change in perfusion parameter ADC during the first 2 weeks of treatment with Cilengitide monotherapy
- Fractional anisotropy (FA) [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]Change in FA during the first 2 weeks of treatment with Cilengitide monotherapy
- Kinetic behavior of [18F]FET uptake [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]Change in tumor amino acid (FET) uptake kinetics during the first 2 weeks of treatment with Cilengitide monotherapy
- Mean spin-lattice relaxation time of unbound protons in water [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]Change in Absolute T1(mean spin-lattice relaxation time of unbound protons in water) during the first 2 weeks of treatment with Cilengitide monotherapy
| Enrollment: | 1 |
| Study Start Date: | August 2012 |
| Study Completion Date: | February 2013 |
| Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Group A = Cilengitide Group
Cilengitide + SoC (Temolozomide + Radiotherapy)
|
Drug: Drug (including placebo)
Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle. Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide. |
|
Active Comparator: Group B = Control Group
SoC (Temolozomide + Radiotherapy)
|
Other: Standard therapy
In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female subject aged ≥ 18 to ≤ 70 years at the time of informed consent signature
- Tumor tissue specimens taken from multimodal imaging-guided stereotactic biopsy must be available for histopathological confirmation of GBM and potential subsequent analysis of tissue molecular markers
- Newly diagnosed histologically proven supratentorial GBM (World Health Organization [WHO] Grade IV)
- Subject with non-resectable GBM
- Available dynamic MRI and FET-PET scan prior to randomization
- Available Gd-MRI performed prior randomization
- ECOG Performance status of 0-2
- Stable or decreasing dose of steroids for >= 5 days prior to randomization
- Given written informed consent
Exclusion Criteria:
- Prior chemotherapy within the last 5 years
- Prior RTX of the head (except for low-dose radiotherapy for Tinea capitis)
- Gross total resection/partial resection (GBM surgery), placement of Gliadel® wafer
- Receiving concurrent investigational agents or receipt of an investigational agent within the past 30 days prior to the first day of intensified imaging (W1D1)
- Prior systemic antiangiogenic therapy
- Inability to undergo dynamic MR or FET-PET imaging
- History of allergic reactions attributed to Gadolinium-based contrast agents for MRI, compounds of similar chemical or biological composition
- Planned major surgery for other diseases
- History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal ulcer, or esophageal ulcer) within 6 months prior to enrollment
- History of other malignant disease or acute malignant disease. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for ≥ 5 years are eligible for this study
- Current or history of bleeding disorders and/or history of thromboembolic events
- Clinically manifest myocardial insufficiency (NYHA III, IV) or history of myocardial infarction during the past 6 months prior to enrollment, uncontrolled arterial hypertension
Contacts and Locations More Information
No publications provided
| Responsible Party: | Merck KGaA |
| ClinicalTrials.gov Identifier: | NCT01558687 History of Changes |
| Other Study ID Numbers: | EMR062041-017, 2011-003794-29 |
| Study First Received: | March 16, 2012 |
| Last Updated: | April 10, 2013 |
| Health Authority: | United States: Food and Drug Administration Germany: Federal Institute for Drugs and Medical Devices Poland: Ministry of Health Switzerland: Swissmedic |
Keywords provided by Merck KGaA:
|
Oncology newly diagnosed inoperable glioblastoma temolozomide radiotherapy dynamic MRI |
Positron emission tomography [18]FET tracer cilengitide World Health Organization [WHO] Grade IV |
Additional relevant MeSH terms:
|
Glioblastoma Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors |
Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |
ClinicalTrials.gov processed this record on May 23, 2013